Positron emission tomography (PET) has proven to be an invaluable tool in the staging and management of disease in oncology; however, [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG) remains the most widely used PET radiopharmaceutical despite the large financial investment in novel radiotracer development. We report our perspective and experience of translating radiopharmaceuticals into clinical studies, discussing the PET development pipeline from a chemistry perspective. We hope that, by identifying potential points of attrition along the pipeline and suggesting solutions to these problems, we may help others take their preclinical radiotracers into human studies. This review focuses primarily on the development of fluorine-18 radiopharmaceuticals, although the broader field of radiometal chemistry is considered where the translation journey is similar.

中文翻译：

---

肿瘤学PET放射性药物临床翻译的化学注意事项。

正电子发射断层扫描（PET）已被证明是肿瘤学分期和管理中不可估量的工具。但是，[ ¹⁸ F]氟脱氧葡萄糖（[ ¹⁸尽管在新型放射性示踪剂开发方面投入了大量资金，但F] FDG仍然是使用最广泛的PET放射性药物。我们报告了将放射性药物转化为临床研究的观点和经验，并从化学角度讨论了PET开发流程。我们希望，通过识别管道中的潜在损耗点并提出解决这些问题的建议，我们可以帮助其他人将其临床前放射性示踪剂带入人体研究。这篇综述主要侧重于氟18放射性药物的开发，尽管在翻译过程相似的情况下考虑了更广泛的放射性金属化学领域。